| 000 | 01785 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518021109.0 | ||
| 264 | 0 | _c20200408 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a2470-9468 | ||
| 024 | 7 |
_a10.1126/sciimmunol.aap9520 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGemta, Lelisa F | |
| 245 | 0 | 0 |
_aImpaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 _h[electronic resource] |
| 260 |
_bScience immunology _c01 2019 |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 |
_aGlucose Transporter Type 1 _xmetabolism |
| 650 | 0 | 4 | _aGlycolysis |
| 650 | 0 | 4 |
_aHepatitis A Virus Cellular Receptor 2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aImmunotherapy, Adoptive |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _ximmunology |
| 650 | 0 | 4 |
_aMelanoma _xgenetics |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aPhosphopyruvate Hydratase _xgenetics |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 700 | 1 | _aSiska, Peter J | |
| 700 | 1 | _aNelson, Marin E | |
| 700 | 1 | _aGao, Xia | |
| 700 | 1 | _aLiu, Xiaojing | |
| 700 | 1 | _aLocasale, Jason W | |
| 700 | 1 | _aYagita, Hideo | |
| 700 | 1 | _aSlingluff, Craig L | |
| 700 | 1 | _aHoehn, Kyle L | |
| 700 | 1 | _aRathmell, Jeffrey C | |
| 700 | 1 | _aBullock, Timothy N J | |
| 773 | 0 |
_tScience immunology _gvol. 4 _gno. 31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1126/sciimmunol.aap9520 _zAvailable from publisher's website |
| 999 |
_c29293988 _d29293988 |
||